Stealth BioTherapeutics Provides Update on Phase 3 Trial of Elamipretide in Primary Mitochondrial Myopathy

Print Friendly, PDF & Email

Primary endpoints of six-minute walk test and Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue Score not met FDA engagement for Barth syndrome and enrollment of Phase 2 trial in geographic atrophy associated with dry age-related macular degeneration (AMD) remain on track for early 2020 BOSTON, MA, USA I […]